Nicox: cash horizon extended to Q4

(CercleFinance.com) - Nicox announced Thursday that it has extended its cash horizon to the fourth quarter of 2025, enabling it to focus on the development of its lead clinical program.


The ophthalmology company said it had received an upfront payment of 500.000 euros as part of a flexible equity financing facility agreed with Vester Finance.

This financing, which will take the form of a capital increase program through the exercise of options, or PACEO, is for a maximum of 10,000,000 shares over a 24-month period.

Assuming full utilization of this financing line, a shareholder holding 1% of the company's capital prior to its implementation would see his stake reduced to 0.87% of the capital.

This fundraising comes at a time when Nicox is preparing a marketing authorization application for its NCX 470, which should be completed in time for a US filing in the first half of 2026 and a potential commercial launch in the first half of 2027.

This is a new eye drop for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Copyright (c) 2025 CercleFinance.com. All rights reserved.